Camille Muller
Psychiatric/Mental Health · Fort Pierce, FLNPI 1790230613
Payments from drug & device makers
Across 482 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$971
- plus $3K from 17 others
What the payments were for
- Food & beverage$11,339100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 93 | $1,923 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $1,539 |
| Neurocrine Biosciences, Inc. | 82 | $1,510 |
| Teva Pharmaceuticals USA, Inc. | 46 | $1,499 |
| Otsuka America Pharmaceutical, Inc. | 53 | $1,396 |
| Johnson & Johnson | 39 | $971 |
| Alkermes, Inc. | 36 | $856 |
| Lundbeck LLC | 17 | $330 |
| E.r. Squibb & Sons, L.L.C. | 14 | $303 |
| Vanda Pharmaceuticals Inc. | 13 | $237 |
| Axsome Therapeutics, Inc. | 2 | $140 |
| Almatica Pharma LLC | 5 | $129 |
| Supernus Pharmaceuticals, Inc. | 7 | $127 |
| Sunovion Pharmaceuticals Inc. | 8 | $111 |
| Corium, LLC | 3 | $46 |
| TMS Neurohealth Centers Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Biogen | 1 | $28 |
| Ironshore Pharmaceuticals Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $24 |
| Livanova USA, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$598
- ARISTADA$468
- VRAYLAR$252
- AUSTEDO$245
- REXULTI$242
- Austedo XR$235
- ABILIFY MAINTENA$119
- ABILIFY ASIMTUFII$119
- UZEDY$119
- ARISTADA INITIO$117
- Auvelity$117
How this compares
$11,353 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $241,703 |
| Invega SustennaPaliperidone Palmitate | 23 | $60,245 |
| RexultiBrexpiprazole | 21 | $41,262 |
| CaplytaLumateperone Tosylate | 13 | $24,813 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $22,522 |
| Aripiprazole | 60 | $7,176 |
| Ziprasidone Hcl | 35 | $4,169 |
| Lisdexamfetamine Dimesylate | 16 | $3,288 |
| Trazodone Hcl | 111 | $2,425 |
| Quetiapine Fumarate | 97 | $2,127 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 14 | $2,080 |
| Bupropion XlBupropion Hcl | 109 | $1,458 |
| Fluoxetine Hcl | 65 | $1,276 |
| Duloxetine Hcl | 54 | $1,250 |
| Risperidone | 72 | $1,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,510 | $241,70329 claims |
| Johnson & JohnsonInvega Sustenna | $971 | $60,24523 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,396 | $41,26221 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,539 | $24,81313 claims |
| Alkermes, Inc.Lybalvi | $856 | $22,52215 claims |
| Almatica Pharma LLCSertraline Hcl | $129 | $40350 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Fort Pierce
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.